Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway
Authors:
Open Access
- 1 January 2018
- journal article
- research article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 8 (12) , 3224-3236
Abstract
Background: Drug resistance is well known as a major obstacle for cancer recurrence and treatment failure, leading to poor survival in pancreatic cancer, which is a highly aggressive tumor. Identifying effective strategies to overcome drug resistance would have a significant clinical impact for patients with pancreatic cancer.Keywords
This publication has 49 references indexed in Scilit:
- The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3Nature Communications, 2016
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resectionRadiation Oncology, 2013
- The cellular level of TRIM31, an RBCC protein overexpressed in gastric cancer, is regulated by multiple mechanisms including the ubiquitin—proteasome systemCell Biology International, 2011
- Characterization of TRIM31, upregulated in gastric adenocarcinoma, as a novel RBCC proteinJournal of Cellular Biochemistry, 2008
- Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell deathOncogene, 2003
- NF-κB in Pancreatic CancerJournal of Gastrointestinal Cancer, 2003
- Efp targets 14-3-3σ for proteolysis and promotes breast tumour growthNature, 2002
- PML is induced by oncogenic ras and promotes premature senescence.2000
- The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.1999